Biocon Limited BIOCON
NSE · Indien · Gesundheitstechnologie
INR 370,70+0,40 (+0,11 %)
Markt geöffnet· · INR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geöffnet· · INR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo®, for the treatment of HER2–positive breast cancer across multiple disease stages.
Biocon’s updated analyst model now points to a fair value of ₹446.89, compared with the earlier estimate of ₹429.67, which translates to a roughly 4% uplift in the price target. Recent analyst commentary links this higher fair value to views on Biocon’s execution quality, earnings visibility, and how the current risk profile compares with that new target. As you read on, you will see how this revised price target fits into the evolving narrative around the stock and what it may mean for your...
Tariff threats from the US are colliding with India’s export surge, and that clash is putting a fresh spotlight on large-cap exporters with heavy US exposure. Some stocks could see pressure if trade friction bites. Others may benefit as supply chains and free trade deals are rewired. This article breaks down three such stocks from the screener and how this news could matter for your portfolio decisions. The three stocks covered below are just a sample from this theme, and the full screen...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.